Neoleukin Therapeutics (NASDAQ:NLTX – Get Free Report) and AEON Biopharma (NASDAQ:AEON – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.
Profitability
This table compares Neoleukin Therapeutics and AEON Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neoleukin Therapeutics | N/A | -37.22% | -30.91% |
| AEON Biopharma | N/A | N/A | -994.63% |
Earnings & Valuation
This table compares Neoleukin Therapeutics and AEON Biopharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neoleukin Therapeutics | N/A | N/A | -$57.56 million | ($3.11) | -6.68 |
| AEON Biopharma | N/A | N/A | -$36.63 million | ($2.43) | -0.39 |
Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Neoleukin Therapeutics and AEON Biopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neoleukin Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| AEON Biopharma | 0 | 1 | 1 | 1 | 3.00 |
Insider and Institutional Ownership
52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 0.9% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
Summary
AEON Biopharma beats Neoleukin Therapeutics on 7 of the 11 factors compared between the two stocks.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
About AEON Biopharma
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
